HIGHLIGHTS
- who: Pasireotide Mifepristone Somatostatin analog and collaborators from the Departments of Medicine and Neurological Surgery, Northwest Pituitary Center, Oregon Health and Science University, Portland, OR, USA have published the research work: Medical management of Cushing’s disease: what is the future?, in the Journal: (JOURNAL)
- what: Cushing's disease is a debilitating condition, with increased morbidity and mortality if biochemical remission/cure not achieved.
- how: This data was recently confirmed by Godbout et_al who treated 30 CD patients with cabergoline up to 6 mg/week.
SUMMARY
There is also . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.